Connect with us

News

RETRANSMISSION – MEDIA AVAILABILITY: CN Police officers available for media interviews during Rail Safety Week

gbafNews28

HOMEWOOD, Ill., Sept. 20, 2020 — CN (TSX: CNR) (NYSE: CNI) is offering members of the media the opportunity to talk with uniformed police officers during Rail Safety Week, from September 21-27, about the importance of rail safety at crossings and the dangers of trespassing.

Members of the CN Police Service will be available for media interviews throughout the week. Providing that social distancing be respected or in a virtual manner, we invite media outlets to contact CN to arrange onsite, in studio or on air interviews. The CN media relations team is also happy to offer visual elements for on camera interviews.

CN will mark Rail Safety Week with a public awareness campaign aimed at reducing the number of collisions and trespassing-related accidents. Throughout the week, CN Police will conduct safety initiatives at commuter stations and railway crossings reminding commuters and motorists about the importance of safety at crossings and the deadly risks of trespassing on railway tracks and property.

Media Contact: Mathieu Gaudreault Senior Advisor Public Affairs and Media Relations (514) 249-4735 [email protected]

Primary Logo

News

Xinhua Silk Road: 137 projects with investment of RMB91.15 bln contracted in east China’s Jiangyin

gbafNews28

BEIJING, Oct. 20, 2020 /PRNewswire/ — 137 projects involving a total investment of 91.15 billion yuan were signed at the Jiangyin Symposium on Economic and Trade Cooperation held on last Friday in Jiangyin city, east China’s Jiangsu province.

Of the total projects, 15 were foreign-invested ones with a total investment of 3.52 billion yuan.

In terms of investment fields, 111 were manufacturing projects with a total investment of 64.02 billion yuan, covering such fields as new energy, new materials, and auto parts. The remaining 26 projects with a total investment of 27.13 billion yuan were service projects related to intelligent warehousing, transportation and logistics, biomedicine, cross-border e-commerce and other areas.

Nearly 500 businessmen from more than ten countries and regions including Italy, the U.K., Japan, the Republic of Korea (ROK) and Israel attended the Jiangyin Symposium on Economic and Trade Cooperation.

During the event, three major projects, namely the e-commerce industrial park of Jiangyin, foreign trade and live-streaming sales promotion festival, as well as China-ROK cross-border e-commerce project, were also launched.

Jiangyin has been ranked first in the list of China’s top 100 counties (cities) in terms of industrial strength for three consecutive years, with its high-end textile and clothing, special steel, high-end equipment manufacturing, special vessels and marine equipment leading the country.

In 2019, Jiangyin became the first county-level city in China with total economic volume exceeding 400 billion yuan.

In recent years, Jiangyin has been taking steps to open wider to the world. It has set up trade ties with nearly 200 countries and regions, and gathered over 3,300 foreign-funded enterprises of various types. A batch of the world’s top 500 enterprises such as CITIC Group, Mitsubishi Group and Doosan has made investment in Jiangyin.

Original link: https://en.imsilkroad.com/p/316914.html

Related Links :

http://imsilkroad.com

Continue Reading

News

Finalist Teams Announced for 2020 Asia Super Team: Reach for the Stars

gbafNews28

Ngan hang TMCP Ban Viet to compete for USD$50,000 prize package

TAIPEI, Oct. 20, 2020 /PRNewswire/ — Asia Super Team is here again. 2020 is the seventh consecutive year the "Taiwanese government" has hosted the international competition together with "Taiwan External Trade Development Council", "TAITRA". This year, the theme is Reach for the Stars, with four-member corporate finalist teams — from Japan, Vietnam, Indonesia, Malaysia, South Korea, Singapore, Thailand, and the Philippines — who have qualified to participate in the November finals competition.

The eight teams are already preparing for the challenge to earn the Asia Super Team title. Due to COVID-19, this will be the first time the competition will be held completely online, so teams can experience Taiwan from the comfort and safety of their own environments. The champion team will win an incentive travel package to Taiwan for their company valued at US$50,000.

Be sure to follow the latest news and developments on the official MEET TAIWAN fan page. Plus enter a lucky draw for one roundtrip ticket to Taiwan by casting a vote. To support the Ngan hang TMCP Ban Viet team from Vietnam, log on to the official website during November 9-15 to cast a vote. Don’t miss out.

  • Event Duration: 18:00 November 9 to 23:59 November 15 (GMT +8)
  • Official Voting Website: asiasuperteam.meettaiwan.com
  • MEET TAIWAN Official Fan Page: www.facebook.com/meettaiwan

There were more than a thousand of applications for the Asia Super Team competition from businesspeople in Vietnam. Congratulations to Ngan hang TMCP Ban Viet for advancing to the second stage finals.

Asia Super Team Finalists:

  • JTB GMT (Japan): With 508 offices in 39 countries, they are a popular travel agency in Japan, promoting and facilitating overseas travelers.
  • NG Bio Co., Ltd. (Korea): A cosmetic manufacturer from Korea, providing popular products such as Pacomeri hand sanitizers throughout Asia.
  • Social Collider (Singapore): A leading co-work space rental company in Singapore, providing space, facilities, and other rental services to social enterprises in Singapore.
  • Balance Gaming Network (Thailand): A leading e-sports company in Thailand, building an e-sports network throughout America, Europe, Australia and South Eastern Asia.
  • St Nivel Tour Sdn Bhd (Malaysia): The leading travel agency in Malaysia, Perak, providing travel assistance to companies and individuals.
  • Teleperformance Philippines (the Philippines): The largest outsourced omnichannel customer experience management company in the Philippines, with more than 30,000 workstations in a variety of businesses.
  • Telkom Indonesia (Indonesia): The biggest telecom company in Indonesia, providing internet, digital communication services, and more.
  • Ngan hang TMCP Ban Viet (Vietnam): One of the leading banks in Vietnam, with 27 years of operation.

For more Asia Super Team information, please check asiasuperteam.meettaiwan.com

Continue Reading

News

Sihuan Pharmaceutical Invests in Phase I Fund of Ascendum Capital Life Technology to Expand its Strategy in Development of Innovative Drugs

gbafNews28

HONG KONG, Oct. 20, 2020 /PRNewswire/ — On 20 October 2020, Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460 "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") announced that its participation in the investment of Phase I Fund of Ascendum Capital Life Technology. The Company looks forward to expand its resources in the development of innovative drugs and accelerate the introduction of overseas innovative drugs in China, strengthen the its resources and development of its international product pipeline and accelerate its product innovation and internationalization. Sihuan Pharmaceutical’s investment and participation in the fund provides valuable support for Ascendum Capital’s future development of medical devices and biopharmaceuticals. This cooperation allows both parties to share resources in a timely manner as it creates a win-win situation.

Sihuan Pharmaceutical was established in 2001. After nearly 20 years pursuing research and development, the company has grown into a large listed pharmaceutical enterprise with an integrated R&D, production and sales system. It is one of the largest suppliers of cardiovascular and cerebrovascular prescription drugs in China. Currently, Sihuan Pharmaceutical’s R&D product pipeline has a total of 80 therapeutics, including innovative drugs with small molecule targets (14 items), biologic drugs with huge market potential (13 items), and generic drugs with high technical barriers (53 items).

In the R&D pipeline, Sihuan Pharmaceutical’s drug portfolio targets major therapeutic areas, including oncology, metabolism, chronic diseases, neuropsychiatric, digestive diseases, anti-infectives, and cardiovascular and cerebrovascular diseases. More than 10 drugs have entered phase III clinical trial or are in the approved production stage. Sihuan Pharmaceutical has a high-quality pre-clinical R&D team of nearly 200 people, including a number of senior scientists with extensive industry experience in internationally renowned pharmaceutical enterprises. The company also has a 200-person clinical development team, which includes more than 70 doctors, masters and overseas returnees. The company features strong research and development capabilities.

Currently, Sihuan Pharmaceutical has a global business development center in the United States that focuses on developing first-in-class oncology, diabetes therapeutics as well as other therapeutic areas with huge clinical needs. The Company also employs international experts to expand and manage business projects in China and abroad. These international experts support Sihuan Pharmaceutical’s global business and accelerate the introduction and deployment of international projects.

In early 2014, Sihuan Pharmaceuticals established a partnership with South Korea’s leading medical aesthetics manufacturer Hugel and codeveloped botulinum toxin and filler products, which will contribute to new business growth. The botulinum toxin product is expected to receive approval before the end of this year, making it the first and only South Korean botulinum toxin product to be approved in China, Sihuan will act as the sole agent for this product.

Sihuan Pharmaceutical has a professional marketing team with nearly 1,000 people, partnering with more than 3,000 distributors. The Company’s sales network covers 14,460 hospitals, nearly 7,500 are secondary and tertiary hospitals, and has 100% coverage rate in the provinces. The Sihuan Pharmaceutical’s sales staff are very professional with the majority of them holding a medical master’s degree or above. The strong sales system is a great benefit to the Company’s future expansion of new products and internationalization.

Sihuan Pharmaceutical has a clear long-term strategic development goal, which is aimed to be an innovation inspired, international pharmaceutical enterprise equipped with technology. The company focuses on the cerebrovascular, oncology diabetes, and aesthetic medicine segments.  It has an independent leading research and development technology platform, rich global product pipeline and mature and excellent sales system. The investment in Ascendum Capital Life Technology Investment Fund is part of the Company’s strategy to expand innovation in new opportunities and develop internationally.

Ascendum Capital Life Technology Investment Fund is a cutting-edge medical investment fund established in July 2020, mainly focusing on the medical and life technology industry. Ms. Shao Ying (former well-known healthcare analyst at Credit Suisse), founder and core managing partner of the Fund, has formed a professional team with extensive industry investment experience and excellent global operation capabilities.

As the Fund’s manager, Ascendum Capital has a network of experts and doctors around the world with strong connections with global pharmaceutical industry giants and potential buyers and can assist Sihuan Pharmaceutical to expand its discovery and introduction of high-quality products. The fund has many international limited partners that provide not only strong financial support, broad and rich source of high-quality international projects, but also unique industrial value-added services to assist invested companies to enhance their value, receive drug registration approval, to advance clinical trial processes and to improve their business operation capabilities.

Ascendum Capital believes that the fund will expand in the medical technology industry, specifically in medical devices and biopharmaceuticals. It intends to introduce foreign advanced technology and products in China to accelerate their research and development and commercialization. It also intends to promote the research and development of products with independent intellectual property rights in China, cultivate and integrate more industry-leading innovative medical device companies, strengthen the integration of the industry and capital, enhance the integrated competitiveness of innovative medical companies, and promote the development of China’s healthcare industry.

Ascendum Capital has strong knowledge of Sihuan Pharmaceutical’s business and development needs as well as a full understanding of the management and Sihuan Pharmaceutical’s founders’ requirements and expectations. With Sihuan Pharmaceutical’s participation, both parties can share project resources more effectively, and expand Sihuan Pharmaceutical’s investment team’s resources while creating a win-win cooperation for both parties.

Sihuan Pharmaceutical participated in the investment of Ascendum Capital. Ascendum Capital has excellent investment resources and flexible exit strategies, and is expected to provide Sihuan Pharmaceutical with excellent investment returns. Additionally, Sihuan Pharmaceutical can obtain first-hand funding and project support by cooperating with top fund managers.

Dr. Che Fengsheng, Chairman and Executive Director of Sihuan Pharmaceutical Holdings Group commented, "The investment in Ascendum Capital is in line with the Group’s goal of promoting and achieving the Company’s strategic transformation through investment. Sihuan Pharmaceutical consistently pursues product innovation, research and development as well as cultivation of high-quality manufacturing enterprises, supplemented with investment, mergers, incubation, holding and spin-offs, to generate a number of independently operated subsidiaries, and help them enter the capital market and enhance the parent company’s value-added."

With management’s unique strategic vision, Sihuan Pharmaceutical is able to pursue the strategy of "innovation-driven, imitation and creation co-exist". Sihuan Pharmaceutical’s subsidiaries are also cooperating together at all levels to promote the transformation of Sihuan Pharmaceutical from a traditional pharmaceutical company into a comprehensive pharmaceutical group, creating the new path to internationalization.

About Sihuan Pharmaceutical Holdings Group Ltd.

Founded in 2001, Sihuan Pharmaceutical Holdings Group Ltd. ("Sihuan Pharmaceutical" or the "Company"), together with its subsidiaries (the "Group") is a pharmaceutical group with integrated research and development ("R&D"), production and marketing and sales capabilities. It is one of the largest suppliers of cardio-cerebral vascular ("CCV") prescription drugs in China. Sihuan Pharmaceutical has an excellent and professional marketing model, a nationwide distribution network, a diversified product portfolio with great market potential, as well as strong R&D capability. The Group continues to increase investment in R&D every year. Because of the continuing efforts over the past decade, Sihuan Pharmaceutical has a R&D platform with over 1,000 researchers conducting more than 110 pharmaceutical research projects. More than 300 patents on innovative drugs have been granted and over 80 of them are overseas patent. The Group’s current pipeline projects cover key therapeutic areas including diabetes, oncology, anti-infectives and non-alcoholic steatohepatitis, etc.

For more information about Sihuan Pharmaceutical, please visit the company website https://www.sihuanpharm.com/.

Related Links :

https://www.sihuanpharm.com/

Continue Reading
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.
gbafNews28 gbafNews28
News2 hours ago

MSG cooperates with Trading Central to help customers identify the best trading opportunities

HONG KONG, Oct. 20, 2020 /PRNewswire/ — Create exclusive analysis tools to help customers identify the best trading opportunities. The...

gbafNews28 gbafNews28
News2 hours ago

Finalist Teams Announced for 2020 Asia Super Team: Reach for the Stars

Balance Gaming Network to compete for USD$50,000 prize package TAIPEI, Oct. 20, 2020 /PRNewswire/ — Asia Super Team is here...

gbafNews28 gbafNews28
News2 hours ago

Sihuan Pharmaceutical Invests in Phase I Fund of Ascendum Capital Life Technology to Expand its Strategy in Development of Innovative Drugs

HONG KONG, Oct. 20, 2020 /PRNewswire/ — On 20 October 2020, Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460 "Sihuan Pharmaceutical"...

gbafNews28 gbafNews28
News2 hours ago

Finalist Teams Announced for 2020 Asia Super Team: Reach for the Stars

Ngan hang TMCP Ban Viet to compete for USD$50,000 prize package TAIPEI, Oct. 20, 2020 /PRNewswire/ — Asia Super Team...

gbafNews28 gbafNews28
News2 hours ago

Xinhua Silk Road: 137 projects with investment of RMB91.15 bln contracted in east China’s Jiangyin

BEIJING, Oct. 20, 2020 /PRNewswire/ — 137 projects involving a total investment of 91.15 billion yuan were signed at the...

gbafNews28 gbafNews28
News2 hours ago

Azbil to Exhibit Online the Latest Automation Technologies and Solutions at Industrial Transformation ASIA-PACIFIC (ITAP)

TOKYO, JAPAN – Media OutReach – 20 October 2020 – Azbil Corporation (Tokyo Stock Exchange Code: 6845) announced that it will participate as...

gbafNews28 gbafNews28
News4 hours ago

Finalist Teams Announced for 2020 Asia Super Team: Reach for the Stars

Teleperformance Philippines to compete for USD$50,000 prize package TAIPEI, Oct. 20, 2020 /PRNewswire/ — Asia Super Team is here again....

gbafNews28 gbafNews28
News4 hours ago

Hong Kong Blockchain Week 2020: Setting DeFi and Blockchain Trends for 2021

November 17th to 19th 2020, speakers and participants will assess the economic and technological rollercoaster of the year 2020,and will...

gbafNews28 gbafNews28
News4 hours ago

SK hynix to Acquire Intel NAND Memory Business

NEWS HIGHLIGHTS SK hynix will pay US $9 billion for the Intel NAND memory and storage business, which includes the...

gbafNews28 gbafNews28
News4 hours ago

Finalist Teams Announced for 2020 Asia Super Team: Reach for the Stars

Social Collider to compete for USD$50,000 prize package TAIPEI, Oct. 20, 2020 /PRNewswire/ — Asia Super Team is here again....